ClinicalTrials.gg
RecruitingNCT06963268SENTOV IIUpdated Dec 19, 2025

Validation of the Sentinel Lymph Node Technique in Early-stage Ovarian Cancer (SENTOV II)

A Phase 3 interventional study of Sentinel Node Technique in Ovarian Neoplasms, sponsored by Instituto de Investigacion Sanitaria La Fe. Recruiting at 1 site in Spain. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-19.

Sponsored by Instituto de Investigacion Sanitaria La Fe · Phase 3, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 268 studies in Ovarian Neoplasms with a site in Spain — 65 open to participants now, 101 under way, 25 of them phase 3. Ovarian Neoplasms · Spain.

Planned enrollment
123rd of 253
200 · median 187
Started
2025
with 18 others
Phase 3
66 of 268
9 open now
Primary completion
2028-06
later than 63 of 100 live
Registered
246th of 268
by date

Among the 268 studies in Ovarian Neoplasms with a site in Spain, this one is the 123rd largest by planned enrollment of the 253 interventional ones that give a count, is one of 19 that started in 2025, is one of 66 in phase 3, reaches primary completion later than 63 of the 100 other live ones, and was the 246th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

65 of the 268 studies in Ovarian Neoplasms with a site in Spain are open now. Recruiting first, the newest first:

59 more — sign in →

All 65 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 268 studies in Ovarian Neoplasms with a site in Spain, or all of them as a file.
02

Study summary

This clinical trial investigates the sentinel lymph node (SLN) technique as a less invasive alternative to conventional lymphadenectomy in patients with early-stage ovarian cancer. The primary objective is to evaluate the effectiveness, safety, and diagnostic accuracy of the SLN approach in detecting lymphatic metastases. By assessing its negative predictive value, the study aims to determine whether the SLN technique can reliably replace systematic pelvic and paraaortic lymphadenectomy. If successful, this technique could minimize surgical morbidity, shorten hospitalization stays, and lower complication rates, ultimately improving patient outcomes.

03

Conditions studied

  • Ovarian Neoplasms

Browse trials for

Keywords

  • Sentinel Node Technique
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed prior to the performance of any procedure related to the clinical trial.
  • Female, 18 years of age or older at the time of inclusion.
  • Patients with a histopathological diagnosis of malignant ovarian tumor in a deferred study (any epithelial histology), in apparent early stage FIGO I-II, proposed for staging surgery, or patients with suspected malignant ovarian tumor in apparent early stage FIGO I-II, who will undergo exploratory laparotomy and operative , and if positive, will undergo staging surgery.

Exclusion criteria

Exclusion Criteria:

  • Failure to obtain or revocation of informed consent.
  • Under 18 years of age at the time of inclusion.
  • Previous history of vascular surgery on the aorta, vena cava, or pelvic vessels.
  • Previous pelvic or paraaortic lymphatic surgery.
  • Previous lymphoma.
  • Previous abdomino-pelvic tumor.
  • Previous allergy to Tc99 or ICG.
  • Pregnancy/Breastfeeding.

Patients who have signed informed consent but do not meet all inclusion criteria and none of the exclusion criteria will be considered as selection failures.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Women >18, with confirmed early-stage ovarian cancer, undergoing staging surgery.

    A 0.2 ml (27 mBq) dose of 99mTc and 0.5 ml (1.25 mg/ml) of ICG is injected subperitoneally in the dorsal or ventral side of the pelvic infundibulum stump, and 0.2 ml (27 mBq) of 99mTc and 1 ml (1.25 mg/ml) of ICG intracervically. Sentinel nodes are located using the auditory signal from the gamma probe and visually via ICG staining with an infrared light system. After 30 minutes, all identified nodes are removed. Deferred histology applies ultra-staging for negative or micrometastatic nodes.

    Procedure: Sentinel Node Technique

Interventions

  • ProcedureSentinel Node Technique

    A 0.2 ml (27 mBq) dose of 99mTc and 0.5 ml (1.25 mg/ml) of ICG is injected subperitoneally in the dorsal or ventral side of the pelvic infundibulum stump, and 0.2 ml (27 mBq) of 99mTc and 1 ml (1.25 mg/ml) of ICG intracervically. Sentinel nodes are located using the auditory signal from the gamma probe and visually via ICG staining with an infrared light system. After 30 minutes, all identified nodes are removed. Deferred histology applies ultra-staging for negative or micrometastatic nodes.

06

What researchers measure

Primary outcomes

  1. Negative predictive value of the sentinel lymph node technique.

    To determine the negative predictive value of the sentinel lymph node technique for detecting lymph node metastases, using pelvic/aortic lymphadenectomy as the Gold Standard.

    Time frame: Postoperative (30 days +/- 10 days)

Secondary outcomes

  1. Concordance of Sentinel Lymph Node Technique vs. Lymphadenectomy

    Evaluate the degree of concordance (sensitivity, specificity, positive predictive value, and diagnostic accuracy) between the sentinel lymph node technique and pelvic/aortic lymphadenectomy (Gold Standard) for detecting lymph node metastasis.

    Time frame: Postoperative (30 days +/- 10 days).

  2. Characterize Sentinel Lymph Node Technique vs. Lymphadenectomy for Metastasis Detection

    Characterize the sentinel lymph node technique for detecting lymph node metastasis using pelvic/aortic lymphadenectomy as the Gold Standard in terms of sensitivity, specificity, positive and negative predictive value, positive and negative likelihood ratios, and effectiveness.

    Time frame: Intraoperative and postoperative (30 days +/- 10 days).

  3. Sample Characterization

    Characterize the sample (through collection of baseline characteristics, medical history, tumor markers, intraoperative findings, surgical procedures, and immediate admission data).

    Time frame: Baseline visit and Intraoperative

  4. Characterize Sentinel Lymph Node Technique Based On Site of Drug Injection

    Characterize the sentinel lymph node technique for detecting lymph node metastasis based on the site of drug injection, using lymphadenectomy as the Gold Standard, in terms of sensitivity, specificity, positive and negative predictive value, positive and negative likelihood ratios, and effectiveness.

    Time frame: Intraoperative and postoperative (30 days +/- 10 days).

  5. Determine Sentinel Lymph Node Procedure Rate

    Determine the sentinel lymph node procedure rate.

    Time frame: Intraoperative and postoperative (30 days +/- 10 days).

  6. Determine the rate of "empty" sentinel lymph node detection.

    Determine the rate of "empty" sentinel lymph node detection.

    Time frame: Postoperative (30 days +/- 10 days).

  7. Determine Pelvic and/or Paraaortic Sentinel Lymph Node Detection Rate

    Determine the detection rate of pelvic and/or paraaortic sentinel lymph nodes.

    Time frame: Intraoperative and postoperative (30 days +/- 10 days).

  8. Identify the anatomical location of the sentinel lymph nodes.

    Identify the anatomical location of the sentinel lymph nodes.

    Time frame: Intraoperative and postoperative (30 days +/- 10 days).

  9. Determine the number of detected lymph nodes.

    Determine the number of detected lymph nodes.

    Time frame: Intraoperative and postoperative (30 days +/- 10 days).

  10. Rate of overstaging with ultrastaging.

    Rate of overstaging with ultrastaging.

    Time frame: Postoperative (30 days +/- 10 days).

  11. Complications related to the sentinel lymph node technique

    Complications related to the sentinel lymph node technique.

    Time frame: Intraoperative and postoperative (30 days +/- 10 days).

  12. Complications related to lymphadenectomy.

    Complications related to lymphadenectomy.

    Time frame: Intraoperative and postoperative (30 days +/- 10 days).

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Lago V, Rey I, Diaz-Feijoo B, Torrent A, Tejerizo A, Muruzabal JC, Veiga-Fernandez A, Utrilla-Layna J, Chacon E, Angeles MA, Diestro MD, Sainz de la Cuesta R, Padilla-Iserte P, Montero B, Dawid De Vera T, Vera V, Domingo S. Validation of the Sentinel Lymph Node Technique in Early-stage Ovarian Cancer (SENTOV II). Int J Gynecol Cancer. 2026 Jul;36(7):102821. doi: 10.1016/j.ijgc.2025.102821. Epub 2025 Nov 21. PubMed 41763980 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Jun 2028, 31 months after the start.

Of 52 non-industry phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 115. This study's planned 31 months is below that.

Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2025
First posted
May 8, 2025
StartActual
Nov 10, 2025
Primary completionEst.
Jun 2028
CompletionEst.
Jun 2028
Last update
Dec 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06963268
Lead sponsor
Instituto de Investigacion Sanitaria La Fe
Collaborators
Hospital Universitario La Fe, Hospital Clinic of Barcelona, Hospital Universitario 12 de Octubre, Hospital Universitario La Paz, Hospital General Universitario Gregorio Marañon, Quirón Madrid University Hospital, Hospital of Navarra, Hospital Son Espases, Hospital Universitari de la Vall de Hebron, Hospital Universitario Fundación Jiménez Díaz, Clinica Universidad de Navarra, Universidad de Navarra
Responsible party
Sponsor
First posted
May 8, 2025
Start date
Nov 10, 2025
Primary completion
Jun 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Dec 19, 2025

Study contacts

Mónica Cebrián Coordinator Clinical Research Area
Contact
investigacion_clinica@iislafe.es
+34961246731

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion